179756-40-2

Upstream product

• 1882-72-0 methyl 2-amino-5-hydroxybenzoate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 233281-62-4 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-[(E)-3-cyanocinnamyl]anthranilate 
• 179756-41-3 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-[(7-cyano-2-naphthyl)methyl]anthranilate 
• 540765-39-7 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-[2-(3-cyanophenoxy)ethyl]anthranilate 
• 540765-42-2 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-{[(3-cyanophenyl)(methyl)carbamoyl]methyl}anthranilate 
• 233281-67-9 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-[(7-cyano-2-naphthyl)methyl]anthranilate 
• 540765-43-3 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-{[(3-cyanophenyl)(methyl)carbamoyl]methyl}anthranilate 
• 233282-02-5 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-{[(3-cyanophenyl)carbamoyl]methyl}anthranilate 
• 233281-63-5 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-[(E)-3-cyanocinnamyl]anthranilate 
• 540765-38-6 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-[3-(3-cyanophenyl)propyl]anthranilate 
• 540765-40-0 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-[2-(3-cyanophenoxy)ethyl]anthranilate 
• 233282-00-3 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-{[(3-cyanophenyl)carbamoyl]methyl}-N-(2,2,2-trifluoroacetyl)anthranilate 
• 233281-98-6 methyl N-benzyloxycarbonylmethyl-5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(2,2,2-trifluoroacetyl)anthranilate 
• 540765-37-5 7-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-1-[(E)-3-cyanocinnamyl]-1H-1,4-benzodiazepine-2,5(3H,4H)-dione 
• 233282-01-4 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-{[(3-cyanophenyl)carbamoyl]methyl}anthranilate 

Relevant academic research and scientific papers

Design, synthesis and biological activity of YM-60828 derivatives. Part 2: Potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template

Compound YM-60828 was previously characterized in our laboratory as a potent, selective and orally-bioavailable Factor Xa (FXa) inhibitor. The L-shape conformation of this compound in the active site of FXa was recognized as an important factor in display

Benzenamine derivatives as anti-coagulants

This invention is directed to benzenamine derivatives of formula (I): wherein A, W, m, n, R1, R2, R3, R4, R5and R6are defined herein. These compounds are useful as anti-coagulants.